Orexigen said it reached a tentative agreement with the FDA to conduct a two-year trial on the heart safety of its pipeline drug Contrave.
Mainly due to safety concerns, the FDA has not approved a new prescription weight loss pill in more than a decade.
Related Articles on Obesity:
Diabetes Group: Bariatric Surgery Fights Type 2 Diabetes in Obese Patients
Half of Americans Expected to be Obese by 2030
Report: Obesity Rates Continued to Rise Last Year
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
